NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16

Virology

Volumn 279, Issue 1, 2001, Pages 361-369

  Pastrana, Diana V ^a   Vass, William C ^a   Lowy, Douglas R ^a   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trial; HPV16; Immunoprophylaxis; Neutralization; Papillomavirus; Pseudovirions; Serotypes; Vaccine; Variants; VLP

Indexed keywords

ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IMMUNOPROPHYLAXIS; MOUSE; NONHUMAN; NORMAL HUMAN; PHYLOGENY; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; SEROTYPE; VACCINATION; VIRION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VOLUNTEER; WART VIRUS;

PAPILLOMAVIRUS; SEMLIKI FOREST VIRUS;

EID: 0035915996     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0702     Document Type: Article

References (51)

1. Prevalence of human papillomavirus in cervical cancer: A worldwide prospective
2. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
3. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease
4. Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy
5. Molecular variants of human papillomavirus-16 from four continents suggest pandemic spread of the virus and its coevolution with humankind
6. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16
7. Divergent human papillomavirus type 16 variants are serologically cross-reactive
8. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies
9. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes
10. Antibody-mediated neutralization in vivo of infectious papillomaviruses
11. Immunization with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomaviruses
12. The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains
13. Focus assay in mouse cells for bovine papillomavirus
14. Human papillomaviruses: General features
15. Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world
16. Prospects for human papillomavirus vaccine development: Emerging HPV vaccines
17. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations
18. Sequence variants of human papillomavirus type 16 in clinical samples permit verification and extension of epidemiological studies and construction of a phylogenetic tree
19. Human papillomaviruses
20. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16
21. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6
22. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
23. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16
24. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
25. Sequence rearrangements in the upstream regulatory region of human papillomavirus type 6: Are these involved in malignant transition?
26. Human papillomavirus type 11 (HPV11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
27. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus
28. HPV vaccine treatment trials proliferate, diversify
29. Evolution of human papillomavirus type 18: An ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups
30. Estimates of the worldwide mortality from 25 cancers in 1990
31. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope
32. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor
33. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes
34. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype
35. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition
36. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins
37. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe
38. Papillomavirus-like particle vaccines for cervical cancer
39. Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening
40. Multiple mechanisms for the inhibition of entry and uncoating of superinfecting Semliki Forest virus
41. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro
42. Intratype variation in 12 human papillomavirus types: A worldwide perspective
43. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
44. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system
45. Generation and neutralization of pseudovirions of human papillomavirus type 33
46. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera
47. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16
48. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1
49. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia
50. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments
51. HPV6b virus like particles are potent immunogens without adjuvant in man